aficamten
aficamten: developed by 1 company · 4 clinical trials tracked · 1 FDA decision.
aficamten evidence translation
What we can confirm
1 FDA record · 4 tracked trials
What it means
What to watch
Prepared research question
How could aficamten → CYTK affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| CYTOKINETICS INC (CYTK) Symptomatic Hypertrophic Cardiomyopathy (HCM); Pediatric; Sy… | Phase 3 |
| CYTOKINETICS INC (CYTK) symptomatic obstructive hypertrophic cardiomyopathy (oHCM) | Approved |
Clinical Trials (4)
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Primary endpoint: Safety Endpoints
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Primary endpoint: Change from baseline in Valsalva left ventricular outflow tract gradient (LVOT-G)
A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Primary endpoint: Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)
A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)
Primary endpoint: Incidence of adverse events observed during dosing of aficamten in patients with HCM
FDA Decisions1 records
Frequently asked questions
Who is developing aficamten?
aficamten is being developed by CYTOKINETICS INC.
How many clinical trials involve aficamten?
BioSniper tracks 4 clinical trials involving aficamten.
What is aficamten's latest FDA decision?
The most recent tracked FDA decision for aficamten is Approval for 1 INDICATIONS AND USAGE MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. ( 1 ), dated December 19, 2025.